Semaglutide lawsuits: what the legal cases mean for UK patients

Step 1: What the semaglutide lawsuits actually allege

The wave of legal action against Novo Nordisk (and, to a lesser extent, Eli Lilly over related medicines) began in the United States in 2023 and has grown substantially since. Plaintiffs claim they developed serious gastrointestinal conditions (most prominently gastroparesis, a condition where the stomach empties too slowly) and that the manufacturers did not warn them clearly enough that this was a possible outcome.

A secondary strand of litigation concerns compounded versions of semaglutide. Because the branded medicines were in short supply in the US market, many patients obtained semaglutide from compounding pharmacies operating outside normal licensing channels. Some suffered harm from incorrectly prepared or contaminated products, and lawsuits have followed. This second category of case is largely irrelevant to the UK, where the licensed Wegovy injection is available through regulated supply chains and compounding at this scale does not occur in the same way.

It is also worth noting what the lawsuits do not claim: they are not alleging that semaglutide is ineffective, nor that it should be withdrawn. The legal argument is about the adequacy of prior warning, not about whether the medicine has value. Courts in the US will decide those questions under US law; they do not bind the MHRA, the NHS, or NICE.

Step 2: How the UK regulatory system handles known side effects

In the UK, medicines are licensed and monitored by the MHRA, which requires manufacturers to maintain an up-to-date Summary of Product Characteristics and a Patient Information Leaflet. When new safety signals emerge (from post-marketing surveillance, Yellow Card reports, or international data) the MHRA issues a Drug Safety Update and, where necessary, requires labelling changes.

Gastroparesis and delayed gastric emptying are acknowledged features of GLP-1 receptor agonists, including semaglutide. Slowing gastric emptying is part of how the medicines work to reduce appetite. The licensed patient information for semaglutide already references gastrointestinal effects, and the NHS provides detailed guidance on what to expect, the NHS semaglutide medicines page covers common and serious side effects clearly.

In January 2026 the MHRA issued a Drug Safety Update specifically about GLP-1 receptor agonist medicines, highlighting acute pancreatitis as a known but infrequent risk requiring urgent medical attention if severe, persistent stomach pain develops. That is the UK system working as intended: a confirmed signal, a formal communication, updated guidance. No lawsuit was required to trigger it.

A question our prescribers hear most weeks is whether lawsuits elsewhere should put someone off starting treatment. The honest answer is that following the litigation story is less useful than reading the Patient Information Leaflet, asking your prescriber about anything you're unsure of, and knowing which symptoms warrant calling 111.

Step 3: What it means for anyone considering semaglutide in the UK today

NICE recommends semaglutide for weight management under specific criteria, and its evidence base (including the STEP 1 trial published in the New England Journal of Medicine, which reported around 15% average weight reduction over 68 weeks) is not in dispute. The medicine remains licensed, clinically recommended, and actively dispensed in the UK. What the lawsuits do underline is the importance of informed consent: every patient should understand the side-effect profile before starting, not discover it afterwards.

For anyone exploring their options, our semaglutide overview covers the full side-effect picture in plain language. If you want to understand what Wegovy costs privately and what is included in a legitimate prescription service, that context sits on its own page. The short version: a proper clinical assessment is not a box-ticking exercise, it is the step that ensures the medicine is appropriate for your specific history, and that you know exactly what to watch for.

Semaglutide is available at different dose stages, and you can read about semaglutide 1, the starting dose that most patients begin their treatment with, to understand what the initial phase involves. As treatment progresses, semaglutide 2 covers the next stage of dosing and what changes to expect along the way. For those who have moved through the earlier stages, semaglutide 3 explains what the higher maintenance dose means for ongoing treatment.

Semaglutide is a prescription-only medicine. No online pharmacy or clinic can legally supply it without a prescriber first reviewing your health information. That clinical review is your first and strongest protection, more reliable than any after-the-fact legal remedy. You can learn more about how our clinical team approaches that process on our about page.

Step 4: If you have already had a side effect you were not warned about

If you are in the UK and believe you experienced a side effect that was not adequately communicated to you, the primary route is the MHRA's Yellow Card reporting scheme. This matters: Yellow Card reports contribute directly to post-market surveillance and can trigger formal safety reviews. Your report genuinely affects what information future patients receive.

You should also contact your prescriber or GP as soon as possible. If the side effect was serious, your GP can refer you, document the case, and support any further steps you choose to take. Whether to pursue legal advice is a personal decision; UK civil law around medicines liability is complex and distinct from the US tort system that underlies most of the current lawsuits. A solicitor specialising in clinical negligence or product liability would be the right starting point for UK-specific legal questions, that falls outside what our clinical team can advise on, but we can always help you understand the side-effect profile and when to seek urgent care.

If you are thinking about starting treatment and want to speak to a prescriber about your personal medical history first, that is exactly what our consultations are for. Speak to our prescribers through a free consultation, there is no commitment, and every question gets a real clinical answer.